Status:
COMPLETED
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Bayer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: * Patients with advanced renal cell carcinoma treated with S...
Detailed Description
Recently, a number of targeted agents have demonstrated single-agent activity in the treatment of advanced renal cell carcinoma. Bevacizumab, a humanized monoclonal antibody directed against VEGF, res...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Eligible patient cases are those that have received Sorafenib (Nexavar) as second-line therapy after Sunitinib (Sutent) or Bevacizumab (Avastin) for first-line therapy or those patients that were treated with Sorafenib (Nexavar) as first-line therapy followed by Sunitinib (Sutent) as secondline therapy.
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00876382
Start Date
May 1 2009
End Date
August 1 2011
Last Update
November 14 2013
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Northeast Arkansas Clinic
Jonesboro, Arkansas, United States, 72401
2
Gulfcoast Oncology Associates
St. Petersburg, Florida, United States, 33705
3
Medical Oncology Associates of Augusta
Augusta, Georgia, United States, 30901
4
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States, 40207